7 Actionable Trading Ideas - Piper Sandler
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
10 Consumer Discretionary Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
10 Information Technology Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Jefferies Maintains Buy on Eli Lilly and Co, Raises Price Target to $957
Jefferies analyst Akash Tewari maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $925 to $957.
Eli Lilly and Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/07/2024 12.05% Jefferies $925 → $957 Maintains Buy 05/14/2024 -1.65% Argus Research $770 → $840 Maintai
'AI Big Ten' Dominance on Display in S&P 500 as Nvidia Heads Into Stock Split
TSMC-Backed U.S. Fund Targets Chip, Robotics, And Hardware Startups With New $300M Fund Backed By Kleiner Perkins And Other Investors
TSMC-Backed U.S. Fund Targets Chip, Robotics, And Hardware Startups With New $300M Fund Backed By Kleiner Perkins And Other Investors
Xbox Game Pass June 2024: Top Games To Play Including The Callisto Protocol, Octopath Traveler
Microsoft Corp. (NASDAQ:MSFT) has announced the first wave of games coming to Xbox Game Pass in June 2024. Highlights include the Octopath Traveler series, The Callisto Protocol, and Still Wakes the D
Rapport Therapeutics Starts Trading Above IPO Price
Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge
U.S. District Judge Karen Marston in Philadelphia is set to preside over litigation involving the popular diabetes and weight-loss drugs Ozempic, Wegovy, and Mounjaro.The Judicial Panel on Multidistri
HP Enterprise Upgraded to Buy on AI Opportunities: Argus
A Closer Look at Visa's Options Market Dynamics
Financial giants have made a conspicuous bullish move on Visa. Our analysis of options history for Visa (NYSE:V) revealed 8 unusual trades.Delving into the details, we found 62% of traders were bullis
Google Says In June 2024, Co Will Update The Advertiser Verification Program To Add A New Optional Verification; New Optional Verification To Verify The Affiliation Of The Advertiser/individual With The Organization They Are Verifying
Google Says In June 2024, Co Will Update The Advertiser Verification Program To Add A New Optional Verification; New Optional Verification To Verify The Affiliation Of The Advertiser/individual With T
US Moves Closer To Imposing Tariffs On Asian Solar Panels Following Agency Vote
US Moves Closer To Imposing Tariffs On Asian Solar Panels Following Agency Vote
Kroger Follows Costco to Offer GLP-1s as Part of Weight Loss Program
Wall Street Reacts To Hot Jobs Report: Stocks Swing As Traders Abandon July Rate Cut Hopes
The May labor market report delivered hotter-than-expected numbers in terms of job gains and wage growth.Last month, U.S. employers added 272,000 nonfarm payrolls, a sharp increase from April's 165,00
FDA Advised Manufacturers Of Authorized Covid Vaccines That Covid-19 Vaccines For Use Beginning In Fall 2024 Should Be Monovalent JN.1 Vaccines
FDA Advised Manufacturers Of Authorized Covid Vaccines That Covid-19 Vaccines For Use Beginning In Fall 2024 Should Be Monovalent JN.1 Vaccines
Market Clubhouse Morning Memo - June 7th, 2024 (Trade Strategy For SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META And TSLA)
Good Morning Traders! In today's Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA. Our proprietary formula, exclusive to Market Clubhouse, dictates thes
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
With more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have surged.However, according to industry observers, inves